Detailed Narrative
Strong Financial Performance in Q4 and FY25
Shilpa Medicare reported a robust Q4 FY25 with revenue growing 15% year-on-year to INR338 crores, contributing to a full-year revenue of INR1,310 crores, up 13%. Gross margin expanded by 200 basis points to 69% in Q4, and EBITDA for the quarter was INR84 crore, marking a 15% YoY growth. The full-year adjusted PAT significantly increased by more than 2.5x to INR97 crore.
Significant Debt Reduction and Improved Leverage
The company successfully reduced its net debt to INR558 crores as of March 31, 2025, down from INR905 crores a year ago. This led to a substantial improvement in the net debt-to-EBITDA ratio, which decreased from 5.8x to 1.6x. Interest costs also saw a 38% year-on-year decline in Q4, with plans to repay the remaining INR75 crore NCD by mid-August 2025 for further reduction.
Diverse Pipeline Progress Across Divisions
Shilpa Medicare is advancing its product pipeline across API, Formulations, and Biologics. In API, the first NCE molecule for an innovator customer completed Phase III clinical studies, with filing expected in FY26. The company also expects to launch Axitinib in Q1 FY26 and Nor-UDCA formulation in H1 FY26. The Biologics division anticipates doubling Adalimumab sales in FY26 and filing Aflibercept in India within the same fiscal year.
Strategic CDMO Expansion and Regulatory Milestones
The CDMO segment is gaining traction, with FY25 revenue at INR158 crores and two new contracts signed in Q4. A large-scale microbial long-term contract for over 5 years was secured. The Biologics facility received EUGMP approval, enhancing its capability to supply to Europe and global markets. The transdermal patch and ODF facilities also received EUGMP certification.
Albumin Project Advances with Key Partnership
The recombinant Albumin manufacturing facility is expected to be commissioned and start product batches in FY26. A strategic partnership with Orion Corporation was secured for exclusive commercialization in Europe for therapeutic use, with scientific advice response expected in Q1 FY26. Phase III clinical studies in India are also planned to commence in FY26.
USFDA Import Alert and Unicycive Approval Delays
While remediation for the USFDA import alert on the formulation manufacturing facility is complete, the company awaits a surprise inspection, which may impact CDMO revenue and new product approvals. The approval for the Unicycive product has also been delayed, though management expects it within FY26 and will provide more clarity in Q2 FY26.
R&D Investment and Future Growth Outlook
The company maintains a consistent R&D spend of INR30-35 crore per quarter, reflecting ongoing pipeline development. Management is optimistic about growth across all divisions in FY26, with generic API business expected to grow in the mid-teens or higher, driven by new product launches and expanded capacities.